Detection of Peritoneal Metastasis of Gastric Cancer by Liquid Biopsy in Peripheral Blood: A Prospective Study

Summary

This study is a prospective, multi-omics, observational study aimed at detecting peritoneal metastasis of gastric cancer by combined assays for methylation of cell-free DNA (cfDNA) and other blood-based biomarkers. The study will enroll 384 participants with gastric cancer.

Eligibility

Inclusion Criteria:

* Inclusion Criteria for Case Arm Participants:

  1. Age 18-74 years at the day of consenting to the study.
  2. Able to provide a written informed consent.
  3. No prior cancer treatment (local or systematic) with either of the following:

     A. Pathologically confirmed gastric cancer diagnosis within 42 days prior to blood draw.

     B. High suspicious for cancer diagnosis by imaging tests or other routine clinical examinations, with confirmed pathological cancer diagnosis within 42 days after the blood draw.
  4. Diagnosis of peritoneal metastasis by laparoscopy with cytology.
* Inclusion Criteria for Control Arm Participants:

  1. Age 18-74 years at the day of consenting to the study.
  2. Able to provide a written informed consent.
  3. No prior cancer treatment (local or systematic) with either of the following:

     A. Pathologically confirmed gastric cancer diagnosis within 42 days prior to blood draw.

     B. High suspicious for cancer diagnosis by imaging tests or other routine clinical examinations, with confirmed pathological cancer diagnosis within 42 days after the blood draw.
  4. No peritoneal metastasis detected by laparoscopy with cytology.

Exclusion Criteria:

* Exclusion Criteria for All Participants:

  1. Insufficient qualified blood samples.
  2. During pregnancy or lactation.
  3. Recipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant.
  4. Recipient of blood transfusion within 7 days prior to blood draw.
  5. Recipient of anti-tumor drugs to treat non-cancer diseases within 30 days prior to blood draw.
  6. With other known malignant tumors or multiple primary tumors.
* Exclusion Criteria for Control Arm Participants:

  1. Insufficient qualified blood samples.
  2. During pregnancy or lactation.
  3. Recipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant.
  4. Recipient of blood transfusion within 7 days prior to blood draw.
  5. Recipient of anti-tumor drugs to treat non-cancer diseases within 30 days prior to blood draw.
  6. With other known malignant tumors or multiple primary tumors.

Conditions1

Browse More Trials